| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Lagadinou D Eleni | |
| Spyridonidis Alexandros | |||
| Zoumbos C Nicholas | |||
| P2860 | cites work | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 |
| Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study | Q24670020 | ||
| Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group | Q27851459 | ||
| Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. | Q27851460 | ||
| A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study | Q28293805 | ||
| Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes | Q33366330 | ||
| Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence | Q33368039 | ||
| Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry | Q33384383 | ||
| Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 | ||
| Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. | Q44836524 | ||
| Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities | Q44869367 | ||
| Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome | Q45026144 | ||
| Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. | Q45038438 | ||
| Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning | Q45138879 | ||
| A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group | Q45244768 | ||
| A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. | Q45995909 | ||
| Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia | Q46201258 | ||
| Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial | Q46236663 | ||
| Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy | Q46437713 | ||
| Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies | Q46616061 | ||
| Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome | Q46658486 | ||
| Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia | Q46676396 | ||
| Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity | Q46819255 | ||
| Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors | Q46847870 | ||
| Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial | Q46949702 | ||
| Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. | Q46974006 | ||
| Acute myeloid leukemia clinical practice guidelines in oncology | Q47604255 | ||
| Management of acute myeloid leukemia in elderly patients | Q33767874 | ||
| A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome | Q33843955 | ||
| Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia | Q33861150 | ||
| The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial | Q34517235 | ||
| A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy | Q34549807 | ||
| Age and acute myeloid leukemia | Q34564663 | ||
| Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. | Q34569095 | ||
| Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients | Q34597777 | ||
| High-dose daunorubicin in older patients with acute myeloid leukemia | Q34612117 | ||
| Acute myeloid leukemia: treatment over 60. | Q34680938 | ||
| On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group | Q35155166 | ||
| Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction | Q35848938 | ||
| Drug therapy for acute myeloid leukemia | Q36115808 | ||
| Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia | Q36824553 | ||
| Prognostic factors in elderly patients with AML and the implications for treatment | Q37007461 | ||
| Acute myeloid leukemia in the elderly: current therapeutic results and perspectives for clinical research | Q37161226 | ||
| Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. | Q37234638 | ||
| Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation | Q37323006 | ||
| Acute myelogenous leukemia in older adults | Q37413855 | ||
| Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities | Q37480178 | ||
| Maximum supportive care, standard conditioning and allogeneic stem cell transplantation for elderly patients with acute myelogenous leukemia | Q37534016 | ||
| Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia | Q38386722 | ||
| Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update | Q39690705 | ||
| A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes | Q39749269 | ||
| Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy | Q41442636 | ||
| Treatment of acute myeloid leukemia | Q41893399 | ||
| Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. | Q42678165 | ||
| Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning | Q43526119 | ||
| Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaem | Q43573116 | ||
| Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study | Q43806484 | ||
| Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study | Q43811535 | ||
| Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group | Q44026953 | ||
| Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment | Q44155422 | ||
| The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial | Q44227814 | ||
| Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia | Q44405234 | ||
| Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. | Q44427722 | ||
| HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies | Q44468881 | ||
| Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. | Q44471803 | ||
| A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. | Q44504713 | ||
| Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation | Q44567746 | ||
| Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning | Q44826910 | ||
| Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. | Q53339364 | ||
| Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia | Q69157759 | ||
| Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture | Q69736957 | ||
| Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy | Q70138881 | ||
| Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party | Q71397114 | ||
| Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study | Q73292530 | ||
| Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years | Q73616348 | ||
| Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases | Q74106097 | ||
| The outcomes and costs of acute myeloid leukemia among the elderly | Q74476532 | ||
| Successful allogeneic bone marrow transplantation in selected patients over 50 years of age--a single institution's experience | Q74667654 | ||
| Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) | Q79233975 | ||
| 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation | Q79364253 | ||
| Survival of elderly patients with acute myeloid leukemia | Q79775520 | ||
| A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment | Q79812026 | ||
| Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation | Q79945430 | ||
| Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and compa | Q80530384 | ||
| Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison | Q81526657 | ||
| Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies | Q81708209 | ||
| Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype | Q81769874 | ||
| Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome | Q82366072 | ||
| Defining conditioning regimens for BMT--recognition of "regimens of intermediate intensity" | Q84088948 | ||
| Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia | Q84342632 | ||
| Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup | Q84500071 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | leukemia | Q29496 |
| acute myeloid leukemia | Q264118 | ||
| P304 | page(s) | 943823 | |
| P577 | publication date | 2010-06-10 | |
| P1433 | published in | Journal of oncology | Q26853876 |
| P1476 | title | Challenges in treating older patients with acute myeloid leukemia | |
| P478 | volume | 2010 |
| Q28076011 | Aberrant splicing and drug resistance in AML |
| Q38285621 | An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. |
| Q36805563 | Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients |
| Q53297116 | Gelatin-coated Gold Nanoparticles as Carriers of FLT3 Inhibitors for Acute Myeloid Leukemia Treatment. |
| Q91286798 | Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index |
| Q101121278 | New strategies to treat AML: novel insights into AML survival pathways and combination therapies |
| Q47232101 | Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. |
| Q35596628 | Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cells |
| Q36975817 | Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia |
| Q36337955 | Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients |
Search more.